Reply to: Standardized 25‐Hydroxyvitamin D Measurements in Parkinson’s Disease Patients With COVID‐19

Cereda, Emanuele; Fasano, Alfonso; Pezzoli, Gianni

doi:10.1002/mds.28211

Cited by 1 publication

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 ); some studies reported data on > 1 pertinent outcome. Of these, there were 52 studies reporting results on obesity prevalence among patients with COVID-19 involving a total of 504,556 cases [ 8 , 9 , 16 – 25 , 31 – 70 ] and data regarding the secondary outcomes were reported in 43 studies [ 8 , 9 , 16 – 25 , 31 , 32 , 34 – 38 , 42 , 43 , 45 – 55 , 57 – 61 , 64 , 67 , 68 , 70 – 72 ]. A study by Chao et al [ 73 ] was exclusively performed on children and thus was not included in the meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

The negative impact of obesity on the occurrence and prognosis of the 2019 novel coronavirus (COVID-19) disease: a systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Purpose The 2019 novel coronavirus (COVID-19) is an emerging pandemic, with a disease course varying from asymptomatic infection to critical disease resulting to death. Recognition of prognostic factors is essential because of its growing prevalence and high clinical costs. This meta-analysis aimed to evaluate the global prevalence of obesity in COVID-19 patients and to investigate whether obesity is a risk factor for the COVID-19, COVID-19 severity, and its poor clinical outcomes including hospitalization, intensive care unit (ICU) admission, need for mechanical ventilation, and mortality. Methods The study protocol was registered in PROSPERO (CRD42020203386). A systematic search of Scopus, Medline, and Web of Sciences was conducted from 31 December 2019 to 1 June 2020 to find pertinent studies. After selection, 54 studies from 10 different countries were included in the quantitative analyses. Pooled odds ratios (OR) with 95% confidence intervals (CIs) were calculated to assess the associations. Results The prevalence of obesity was 33% (95% CI 30.0%-35.0%) among patients with COVID-19. Obesity was significantly associated with susceptibility to COVID-19 (OR = 2.42, 95% CI 1.58-3.70; moderate certainty) and COVID-19 severity (OR = 1.62, 95% CI 1.48-1.76; low certainty). Furthermore, obesity was a significant risk factor for hospitalization (OR = 1.75, 95% CI 1.47-2.09; very low certainty), mechanical ventilation (OR = 2.24, 95% CI 1.70-2.94; low certainty), intensive care unit (ICU) admission (OR = 1.75, 95% CI 1.38-2.22; low certainty), and death (OR = 1.23, 95% CI 1.06-1.41; low certainty) in COVID-19 patients. In the subgroup analyses, these associations were supported by the majority of subgroups. Conclusion Obesity is associated with COVID-19, need for hospitalization, mechanical ventilation, ICU admission, and death due to COVID-19. Level of evidence Level I, systematic reviews and meta-analyses.

show abstract